OCX Quote, Financials, Valuation and Earnings

Fonar has a net margin of -2255.11% compared to OncoCyte's net margin of 7.87%. OncoCyte's return on equity of -581.11% beat Fonar's return on equity of 4.95%.

OncoCyte has a consensus price target of $4.42, signalling upside risk potential of 59.45%. On the other hand Fonar has an analysts' consensus of -- which suggests that it could fall by --. Given that OncoCyte has higher upside potential than Fonar, analysts believe OncoCyte is more attractive than Fonar.

OncoCyte has a beta of 0.953, which suggesting that the stock is 4.749% less volatile than S&P 500. In comparison Fonar has a beta of 1.003, suggesting its more volatile than the S&P 500 by 0.30600000000001%.

OncoCyte has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Fonar offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. OncoCyte pays -- of its earnings as a dividend. Fonar pays out -- of its earnings as a dividend.

OncoCyte quarterly revenues are $1.5M, which are smaller than Fonar quarterly revenues of $25M. OncoCyte's net income of -$33.5M is lower than Fonar's net income of $2M. Notably, OncoCyte's price-to-earnings ratio is -- while Fonar's PE ratio is 10.71x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for OncoCyte is 19.24x versus 0.78x for Fonar. Usually stocks with elevated PS ratios are considered overvalued.

ProPhase Labs has a net margin of -2255.11% compared to OncoCyte's net margin of -209.38%. OncoCyte's return on equity of -581.11% beat ProPhase Labs's return on equity of -59.59%.

OncoCyte has a consensus price target of $4.42, signalling upside risk potential of 59.45%. On the other hand ProPhase Labs has an analysts' consensus of $13.80 which suggests that it could grow by 3958.82%. Given that ProPhase Labs has higher upside potential than OncoCyte, analysts believe ProPhase Labs is more attractive than OncoCyte.

OncoCyte has a beta of 0.953, which suggesting that the stock is 4.749% less volatile than S&P 500. In comparison ProPhase Labs has a beta of -0.472, suggesting its less volatile than the S&P 500 by 147.175%.

OncoCyte has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. ProPhase Labs offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. OncoCyte pays -- of its earnings as a dividend. ProPhase Labs pays out -- of its earnings as a dividend.

OncoCyte quarterly revenues are $1.5M, which are smaller than ProPhase Labs quarterly revenues of $3.1M. OncoCyte's net income of -$33.5M is lower than ProPhase Labs's net income of -$6.6M. Notably, OncoCyte's price-to-earnings ratio is -- while ProPhase Labs's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for OncoCyte is 19.24x versus 1.03x for ProPhase Labs. Usually stocks with elevated PS ratios are considered overvalued.

Veracyte has a net margin of -2255.11% compared to OncoCyte's net margin of 6.16%. OncoCyte's return on equity of -581.11% beat Veracyte's return on equity of 2.85%.

OncoCyte has a consensus price target of $4.42, signalling upside risk potential of 59.45%. On the other hand Veracyte has an analysts' consensus of $40.00 which suggests that it could grow by 36.47%. Given that OncoCyte has higher upside potential than Veracyte, analysts believe OncoCyte is more attractive than Veracyte.

OncoCyte has a beta of 0.953, which suggesting that the stock is 4.749% less volatile than S&P 500. In comparison Veracyte has a beta of 2.145, suggesting its more volatile than the S&P 500 by 114.466%.

OncoCyte has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Veracyte offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. OncoCyte pays -- of its earnings as a dividend. Veracyte pays out -- of its earnings as a dividend.

OncoCyte quarterly revenues are $1.5M, which are smaller than Veracyte quarterly revenues of $114.5M. OncoCyte's net income of -$33.5M is lower than Veracyte's net income of $7M. Notably, OncoCyte's price-to-earnings ratio is -- while Veracyte's PE ratio is 71.49x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for OncoCyte is 19.24x versus 5.00x for Veracyte. Usually stocks with elevated PS ratios are considered overvalued.

XWELL has a net margin of -2255.11% compared to OncoCyte's net margin of -56.4%. OncoCyte's return on equity of -581.11% beat XWELL's return on equity of -71.82%.

OncoCyte has a consensus price target of $4.42, signalling upside risk potential of 59.45%. On the other hand XWELL has an analysts' consensus of -- which suggests that it could grow by 669.23%. Given that XWELL has higher upside potential than OncoCyte, analysts believe XWELL is more attractive than OncoCyte.

OncoCyte has a beta of 0.953, which suggesting that the stock is 4.749% less volatile than S&P 500. In comparison XWELL has a beta of 1.014, suggesting its more volatile than the S&P 500 by 1.396%.

OncoCyte has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. XWELL offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. OncoCyte pays -- of its earnings as a dividend. XWELL pays out -- of its earnings as a dividend.

OncoCyte quarterly revenues are $1.5M, which are smaller than XWELL quarterly revenues of $8.4M. OncoCyte's net income of -$33.5M is lower than XWELL's net income of -$4.8M. Notably, OncoCyte's price-to-earnings ratio is -- while XWELL's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for OncoCyte is 19.24x versus 0.12x for XWELL. Usually stocks with elevated PS ratios are considered overvalued.